ASH 2019: Good News for Myeloma Treatment Today, Still Addressing Race-Associated Risks

Respected myeloma expert, Dr. Ajay Kumar Nooka, provides an update from the 61st American Society of Hematology (ASH) meeting. Dr. Nooka shares why this is a good time in myeloma research and the important work that remains around myeloma treatment disparities for people of color.

Ajay K. Nooka, myeloma minority populations, multiple myeloma, American Society of Clinical Oncology 2019, CAR T cell, racial disparities, BiTES, myeloma Hispanics, myeloma education, myeloma African American, Emory University School of Medicine, access to myeloma care, minority myeloma access, stem cell transplant, NCDB, National Cancer Database, clinical trial African American

About this expert

Ajay K. Nooka, MD, MPH, FACP

Associate Professor of Hematology and Medical Oncology

Emory University School of Medicine

Transcript

Rebecca Law:

Dr. Nooka, do you feel this is a good time for patients living with myeloma?

 

Dr. Ajay Nooka:

This is a really good time with a lot of improvements in myeloma. We’ve seen significant improvements over the last 20 years, but this is a time where we are seeing the benefits of what has really happened over the last 20 years in terms of the objective numbers, so that’s great news. We have newer forms of cellular therapies, the CAR T cells, the BiTES, the ADC’s – those are available to all of the myeloma patients nowadays. 


This is all good news for the patients, for the providers, for the patient families and we tend to see this field to be expanding more and offering more therapeutic options.

 

Rebecca Law:

Can you talk about the racial disparities and race-associated risks observed in the treatment of myeloma patients?

 

Dr. Ajay Nooka:

Myeloma is a disease that presents very early in African Americans, almost 5 years earlier in African Americans compared to Caucasians. So maybe the age of diagnosis in Caucasian populations is 69 years and in African Americans it is 64 years or so. So, it tends to present younger. It also has a lot of preponderance for the male population, so if I have to put it in the perspective, an African American male has 4 times higher rate of having myeloma compared to a Caucasian female. SO again, as we talked about, there’s a huge biological aspect that we need to understand more, why this is the case. 

 

From a perspective of access to care, there are disparities that we see mostly in the minorities. African Americans as well as Hispanics tend to have a longer period of time for diagnosis, longer period to access initial treatment. And lesser amounts of stem cell transplant availability for the monitories compared to the Caucasian patients. This has been shown multiple times, again and again. 


What’s really interesting in this meeting is that there has been a lot of large database integrations, including one database called the National Cancer Database (NCBD) where people have looked at 20 year history of how these treatments have panned out. Which of the minority populations or which subset of patients gained the most benefit over the last 20 years? And we see minorities have gotten a lot of improvement and a lot of access to the care over the last 20 years, but that’s not the end of the story, we have to catch up a lot more. 

 

Rebecca Law:

How are knowledge gaps about racial disparities in multiple myeloma being closed?

 

Dr. Ajay Nooka:

So, number one, education and awareness is the biggest gap that we tend to see -- or the most objective way of saying it. So education about development of clinical trials, the ability to participate in the clinical trials. To give you an example, if you take the entire clinical trials and select a pool of all these drugs, the clinical trial participation in African Americans is around 5% or even lesser, so that does not present a true demographic. So what we need is more education to take off the fear of what a clinical trial is, more education to empower them about the availability of the treatments -- make them aware of what is out there for them. Involve people that are really there -- in terms of support groups -- to make the patients aware there are clinical trials.

 

Rebecca Law:

Dr. Nooka, thank you for your time today

 

Rebecca Law

Rebecca graduated from University of San Francisco with a degree in applied economics, focusing on marketing, program management and event management. Her experience is unmatched when it comes to aligning program scope with strategic business objectives. Rebecca has an extensive background in managing marketing campaigns and is highly skilled at communicating with a variety of audiences.

Related Content

pavlos_msaouel.jpg.resize.405.575_edited

Microcosms of Injustice Found Throughout Sickle Cell Disease

Dr. Campbell describes the inequities and injustices throughout the sickle cell community. He presents an example of a patient who almost died because she was not listened to. Physicians must listen to patients with sickle cell disease because their complaints may be a preceding symptom of severe complications.

pavlos_msaouel.jpg.resize.405.575_edited

Is Sickle Cell Disease a Genetic Defense Against COVID-19?

Dr. Msaouel answers questions from the Sickle Cell community. If the disease or trait evolved as a defense against Malaria, does the reported effectiveness of anti-malaria drugs like hydroxychloroquine (Plaquenil) mean that sickle cell patients have natural resistance to the novel coronavirus, COVID-19?

pavlos_msaouel.jpg.resize.405.575_edited

Are Sickle Cell Disease Patients More Susceptible to Renal Medullary Carcinoma?

Dr. Pavlos Msaouel of The University of Texas MD Anderson Cancer Center discusses whether patients with sickle cell disease or who carry the sickle cell trait may be at increased risk for renal medullary carcinoma (RMC).

The information on Diverse Health Hub is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the expert advice of your healthcare team.

© 2020 Diverse Health Hub